Asian Science Citation Index is committed to provide an authoritative, trusted and significant information by the coverage of the most important and influential journals to meet the needs of the global scientific community.  
ASCI Database
308-Lasani Town,
Sargodha Road,
Faisalabad, Pakistan
Fax: +92-41-8815544
Contact Via Web
Suggest a Journal
Japanese Journal of Clinical Oncology
Year: 2009  |  Volume: 39  |  Issue: 10  |  Page No.: 651 - 656

No Association Between CYP2D6*10 Genotype and Survival of Node-negative Japanese Breast Cancer Patients Receiving Adjuvant Tamoxifen Treatment

T Toyama, H Yamashita, H Sugiura, N Kondo, H Iwase and Y. Fujii    

Abstract: Objective

The CYP2D6 enzyme plays a major role in converting tamoxifen to its active metabolites. We investigated whether there is an association between the CYP2D6*10 allele and clinical outcome in node-negative Japanese breast cancer patients.

Methods

CYP2D6 genotyping was performed in 154 node-negative breast cancer patients who had received adjuvant tamoxifen treatment alone. The CYP2D6 genotypes were determined using the TaqMan Allelic Discrimination Assay.

Results

Eighteen percent (28 of 154) of the patients carried the CYP2D6*10/*10 genotype, 40% the CYP2D6 wild-type (wt)/*10 genotype and 42% the CYP2D6 wt/wt genotype. There were no discernible correlations between clinicopathologic parameters and the CYP2D6*10 genotype. Next, we determined whether there was a correlation between the CYP2D6*10 genotype and survival and found that the clinical outcome for patients carrying the CYP2D6*10/*10 genotype was similar to those with other genotypes.

Conclusions

Our results suggest that the CYP2D6*10 genotype is unlikely to have any clinical significance for prognosis of node-negative Japanese breast cancer patients receiving adjuvant tamoxifen alone.

View Fulltext    |   Related Articles   |   Back
   
 
 
 
  Related Articles

No Article Found
 
 
 
Copyright   |   Desclaimer   |    Privacy Policy   |   Browsers   |   Accessibility